Summary & Overview
HCPCS Level II J2426: Paliperidone Palmitate Extended-Release Injection, 1 mg
HCPCS Level II code J2426 denotes a 1 mg unit of paliperidone palmitate extended release (Invega Sustenna) supplied for injection. This code is used to report the drug product itself for administration of a long‑acting injectable antipsychotic, a treatment modality with national relevance for managing schizophrenia and schizoaffective disorder where adherence to oral medication is challenging. Accurate coding ensures appropriate tracking of utilization and payment for this high‑cost, specialty pharmaceutical.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of benchmark considerations, clinical context for use of long‑acting injectable paliperidone palmitate, and commonly applied billing modifiers and settings for service delivery. The publication highlights how J2426 is used across outpatient and ambulatory behavioral health settings, summarizes payer coverage patterns, and outlines typical claims-line elements relevant to billing and reimbursement workflows.
This resource is intended for billing professionals, revenue cycle staff, and clinical administrators seeking a national summary of the code’s purpose, common use cases, and where to expect this service to be delivered.
Billing Code Overview
HCPCS Level II code J2426 represents an injection of paliperidone palmitate extended release (Invega Sustenna), 1 mg. This code describes the drug product and unit dosing for administration of a long-acting injectable antipsychotic formulation.
Service Type: Drug administration (long‑acting injectable antipsychotic)
Typical Site of Service: Outpatient clinic, psychiatric clinic, behavioral health center, or other ambulatory care settings where long‑acting injectable antipsychotic treatments are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 32-year-old adult with a diagnosis of schizophrenia presents to an outpatient behavioral health clinic for a scheduled long-acting antipsychotic administration. The patient receives J2426 (paliperidone palmitate extended release, 1 mg) administered intramuscularly as part of a maintenance dosing regimen following prior initiation with the appropriate loading dose per product labeling. The clinical workflow includes verification of the most recent psychiatric assessment and medication reconciliation, screening for contraindications and allergies, informed consent confirmation, checking prior authorization and benefit coverage with the payer, preparation of the product according to manufacturer instructions, and administration by a qualified clinician (psychiatric nurse or licensed practitioner). Post-injection observation for immediate adverse reaction is documented, and dosage, lot number, injection site, and patient response are recorded in the medical record. Billing is submitted using the HCPCS Level II code J2426 with an applicable modifier to reflect payer-specific circumstances (for example, modifier CO for patient responsibility or JW for discarded drug), and the encounter is supported by an appropriate ICD-10 psychiatric diagnosis on the claim and in the chart. Typical site of service is outpatient behavioral health clinic, psychiatric clinic, community mental health center, or an outpatient infusion/injection suite within an ambulatory care setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|